Women's Cancer News
Apr. 30, 2014

ASTRO issues guideline recommendations for radiation therapy in endometrial cancer
HemOnc Today
The American Society for Radiation Oncology recently issued a new guideline, “The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline,” that details the use of adjuvant radiation therapy in the treatment of endometrial cancer.More

HPV test for first-line cervical screen: Questions on use
Medscape (Free login required)
When the cobas HPV Test (Roche Molecular Systems) was approved for first-line screening of primary cervical cancer by the US Food and Drug Administration (FDA) last week, how and when it should be used was not addressed. The Society of Gynecologic Oncology (SGO) is working with the American Society for Colposcopy and Cervical Pathology (ASCCP) to produce interim guidelines on the use of the HPV test in first-line screening, but for now there are more questions than answers, and many opinions. Two experts told Medscape Medical News how they envisage its use. More

Multiple-gene sequencing IDs mutations in non-BRCA genes
HealthDay News via Doctors Lounge
A considerable number of women testing negative for BRCA1/2 may have pathogenic mutations in other genes, according to a study published online April 14 in the Journal of Clinical Oncology. "Our study demonstrates an early signal for the clinical relevance of multiple-gene sequencing and provides a strong rationale for future research to define its most effective use," the authors write.More

Researchers identify mechanism of cancer caused by loss of BRCA1 and BRCA2 gene function
Medical Xpress
Investigators at Beth Israel Deaconess Medical Center (BIDMC) report a new mechanism by which BRCA gene loss may accelerate cancer-promoting chromosome rearrangements. The new findings, published online in the April 28 issue of Nature, explain how the loss of BRCA1 or BRCA2 function impairs homologous recombination (HR), a normally accurate repair process used to fix DNA breaks, and actually stimulates faulty error-prone HR repair.More

Glow-in-dark surgery may help cancer patients
Operating in the dark would be challenging for most surgeons. But for Indiana University Health's Dr. Emma Rossi, a dimly lit room can be as critical as a scalpel. Rossi has been testing a new procedure to track the spread of gynecological cancers. She injects a fluorescent dye that glows in the dark into a patient and dims the lights in the operating room. Then she uses infrared imaging to track the path the cancer might have taken.More

Researchers generate immunity against tumor vessel protein
Science Codex
A group of researchers from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania is pursuing this strategy by employing a novel DNA vaccine to kill cancer, not by attacking tumor cells, but targeting the blood vessels that keep them alive. The vaccine also indirectly creates an immune response to the tumor itself, amplifying the attack by a phenomenon called epitope spreading. More

Imaging gives clearer picture of cancer drugs' chances of success
Medical Xpress
The quest for new cancer treatments could be revolutionized by advances in technology that can visualize living cells and tissues, scientists claim. Leading edge imaging techniques will make it easier to identify which are the most promising new drugs to take forward for patient testing, a review of the technology suggests. Applying such techniques early in the drug discovery process could improve the success rate of new medicines by helping to rule out drugs that are unlikely to work. Researchers are leading the way in using biological imaging to make the development of new cancer treatments more efficient.More

New approach may overcome breast cancer resistance to HER2-targeted therapies
Oncology Nurse Advisor
Resistance to a combination of human epidermal growth factor receptor 2 (HER2)-targeted therapies, trastuzumab and lapatinib, was associated with elevated activation of a group of proteins called fibroblast growth factor receptors (FGFRs), which are the target of a number of drugs currently being developed. These preclinical results were presented at the American Association for Cancer Research 2014 Annual Meeting, in San Diego, California.More